Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Slides:

Advertisements

Similar presentations

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

Advertisements

J Clin Oncol 28: R2 소예리 / Prof. 이재진. INTRODUCTION EGFR is overexpressed in 70-80% of pts with advanced colorectal cancer EGFR dysregulation:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Talking to Patients About HCV Treatment

Patient Case 1 Patient Case 1: PET/CT Scan.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

An Endocrinology Clinic in Dyslipidemia

Advanced NSCLC Without Actionable Mutations

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

The Nurse View.

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Updates in Lung Cancer: Insights From Vienna

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

Resistant Hypertension

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Clinical Considerations in Evidence-based Management of GIST

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Tailoring Hemophilia Prophylaxis Therapy

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Best Practices in Metastatic Colorectal Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

From Symptom Management to Communication in Advanced GI Cancers

Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Moving Care Forward in Advanced NSCLC

Using Heart Rate as a Biomarker in Clinical Practice.

Maintenance Therapy in Advanced Ovarian Cancer

Immune Checkpoint Inhibitors in Lung Cancer

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Challenges in LA SCCHN.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Optimizing Characterization of NSCLC Through Specialty Collaboration

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Assessing the Burden of Hyperkalemia

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Educational Objectives

AMD Therapy: Where Are We Now and Where Are We Going?

Checkpoint Inhibitors in First-Line Advanced NSCLC

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Assessing the Burden of Hyperkalemia

Third-Generation EGFR TKIs

Clinical Considerations in Evidence-based Management of GIST

The Changing Goals of CML Therapy

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Real-World Evidence.

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

New Options for the Treatment of Hepatocellular Carcinoma

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Treatment Advances for RA

PCSK9 Inhibitors and Real-World Evidence

Updates in Best Practices in Non-Small Cell Lung Cancer

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC

EGFR Inhibitors for NSCLC A Paradigm Shift in Treatment

Overview of Nurses' Role in Managing Patients With Lung Cancer

Case 68-Year-Old Woman

Symptoms in a Patient With Newly Diagnosed NSCLC

Molecular Profiling of NSCLC

Case (cont)

Therapies for EGFR-Positive NSCLC

Initial Conversations With the Patient

Notable Adverse Effects of EGFR TKIs

Skin Rash

Prevalence of Rash With EGFR Inhibitors

Rash and EGFR Inhibitors Improved Outcomes in NSCLC

Strategies to Prevent Dermatologic Toxicities

STEPP Study Preemptive vs Reactive Management of Skin Toxicities

MASCC Recommendations for Prevention of Rash

Case (cont)

MASCC Recommendations for Treatment of Rash

Other Adverse Effects of EGFR TKIs

Paronychia

Scalp Rash

Dose Reductions

Management of Other Adverse Effects

Precautions With Concurrent Medications

Case (cont)

Development of Acquired Resistance to EGFR TKIs

Osimertinib: Efficacy and Safety

Case (cont)

Take-Home Messages

Abbreviations

Abbreviations (cont)